Intelligence Feed event · Equity · 2026-09-03

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM

    Question

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM

    Direct answer

    Revolution Medicines announced that the New England Journal of Medicine published clinical results from its Phase 1/2 study of RASONQUE (daraxonrasib). The trial demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months in pre-treated RAS mutant non-small cell lung cancer cohorts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/revolution-medicines-publishes-phase-1-2-data-for-daraxonrasib-in-nejm-35c5fb

    EQUITY
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
    Revolution Medicines announced that the New England Journal of Medicine published clinical results from its Phase 1/2 study of RASONQUE (daraxonrasib). The trial demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months in pre-treated RAS mutant non-small cell lung cancer cohorts.
    RVMD
    Impact
    67
    SEP 3
    SIG
    88%
    RVMD
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
    Revolution Medicines announced that the New England Journal of Medicine published clinical results from its Phase 1/2 study of RASONQUE (daraxonrasib). The trial demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months in pre-treated RAS mutant non-small cell lung cancer cohorts.
    → Statistically meaningful response rates in previously treated RAS mutant NSCLC de-risk Phase 3 approval timelines, increasing the net present value of RVMD oncology pipeline assets.
    Impact
    Revolution Medicines announced that the New England Journal of Medicine published clinical results from its Phase 1/2 study of RASONQUE (daraxonrasib). The trial demonstrated a 42% objective response rate alongside a median overall survival of 16.0 months in pre-treated RAS mutant non-small cell lung cancer cohorts.
    Affected
    RVMD
    Transmission
    Statistically meaningful response rates in previously treated RAS mutant NSCLC de-risk Phase 3 approval timelines, increasing the net present value of RVMD oncology pipeline assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical pipeline de-risking and addressable market validationUp1-5dNEJM publication showed 42% ORR and 16.0 months median OS in RAS mutant NSCLC.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month